TIME RELATED BENEFIT OF ANTIPLATELET THERAPY ON CORONARY REPERFUSION IN ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) PATIENTS

Background: The goal of STEMI treatment is early reperfusion. The new oral P2Y12 inhibitors (P2Y12-I) prasugrel and ticagrelor demonstrated to improve angiographic results of primary percutaneous coronary intervention (pPCI) and clinical prognosis, but their onset of action is significantly impaired